Seralite® for multiple myeloma and other B cell dyscrasias
NIHR HSRIC
Record ID 32016000468
English
Authors' objectives:
Seralite® is a rapid diagnostic device that has been developed by Abingdon Health for the diagnosis and monitoring of multiple myeloma and other B cell Dyscrasias such as Monoclonal Gammopathy of Undetermined Significance (MGUS). Seralite® measures Kappa (κ) and Lambda (λ) immunoglobulin free light chains (FLCs) in serum using highly specific, anti-κ and anti-λ monoclonal antibodies (mAbs) which are conjugated to gold nanoparticles and incorporated into a lateral flow device.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/seralite-for-multiple-myeloma-and-other-b-cell-dyscrasias/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- B-Lymphocytes
- Hyperplasia
- Multiple Myeloma
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.